Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations

Corrado Girmenia, Michele Cavo, Massimo Offidani, Francesco Scaglione, Alessandro Corso, Francesco Di Raimondo, Pellegrino Musto, Maria Teresa Petrucci, Giovanni Barosi

Research output: Contribution to journalArticle

Abstract

The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors, immunoregulatory drugs and monoclonal antibodies, has improved the outcomes of patients, but in parallel has changed the frequency and epidemiology of infections. Hence, the great strides in the indications and use of new active treatments for MM need parallel progresses on the best approach to prophylaxis and supportive therapy for infections. Moving from the recognition that the above issue represents an unmet clinical need in MM, an expert panel assessed the scientific literature and composed a framework of recommendations for optimal infection control in patients candidate to active treatment for MM. The present publication represents a consensus document from questionnaires and consensus meetings held during 2017. The issues tackled in the project dealt with: infectious risk assessment, risk management and prophylaxis, intravenous immunoglobulin replacement therapy, antiviral and antibacterial vaccination. Considering the lack of conclusive and/or enough large studies for certain topics several recommendations derived from the personal experience of the experts.

Original languageEnglish
JournalBlood Reviews
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Multiple Myeloma
Literature
Proteasome Inhibitors
Passive Immunization
Intravenous Immunoglobulins
Risk Management
Therapeutics
Infection Control
Infection
Antiviral Agents
Vaccination
Epidemiology
Monoclonal Antibodies
Pharmaceutical Preparations

Keywords

  • Infections
  • Multiple myeloma
  • Prophylaxis
  • Vaccination

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Management of infectious complications in multiple myeloma patients : Expert panel consensus-based recommendations. / Girmenia, Corrado; Cavo, Michele; Offidani, Massimo; Scaglione, Francesco; Corso, Alessandro; Di Raimondo, Francesco; Musto, Pellegrino; Petrucci, Maria Teresa; Barosi, Giovanni.

In: Blood Reviews, 01.01.2019.

Research output: Contribution to journalArticle

Girmenia, Corrado ; Cavo, Michele ; Offidani, Massimo ; Scaglione, Francesco ; Corso, Alessandro ; Di Raimondo, Francesco ; Musto, Pellegrino ; Petrucci, Maria Teresa ; Barosi, Giovanni. / Management of infectious complications in multiple myeloma patients : Expert panel consensus-based recommendations. In: Blood Reviews. 2019.
@article{98d749a3a9ec4b368e9077f01e9829ad,
title = "Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations",
abstract = "The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors, immunoregulatory drugs and monoclonal antibodies, has improved the outcomes of patients, but in parallel has changed the frequency and epidemiology of infections. Hence, the great strides in the indications and use of new active treatments for MM need parallel progresses on the best approach to prophylaxis and supportive therapy for infections. Moving from the recognition that the above issue represents an unmet clinical need in MM, an expert panel assessed the scientific literature and composed a framework of recommendations for optimal infection control in patients candidate to active treatment for MM. The present publication represents a consensus document from questionnaires and consensus meetings held during 2017. The issues tackled in the project dealt with: infectious risk assessment, risk management and prophylaxis, intravenous immunoglobulin replacement therapy, antiviral and antibacterial vaccination. Considering the lack of conclusive and/or enough large studies for certain topics several recommendations derived from the personal experience of the experts.",
keywords = "Infections, Multiple myeloma, Prophylaxis, Vaccination",
author = "Corrado Girmenia and Michele Cavo and Massimo Offidani and Francesco Scaglione and Alessandro Corso and {Di Raimondo}, Francesco and Pellegrino Musto and Petrucci, {Maria Teresa} and Giovanni Barosi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.blre.2019.01.001",
language = "English",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Management of infectious complications in multiple myeloma patients

T2 - Expert panel consensus-based recommendations

AU - Girmenia, Corrado

AU - Cavo, Michele

AU - Offidani, Massimo

AU - Scaglione, Francesco

AU - Corso, Alessandro

AU - Di Raimondo, Francesco

AU - Musto, Pellegrino

AU - Petrucci, Maria Teresa

AU - Barosi, Giovanni

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors, immunoregulatory drugs and monoclonal antibodies, has improved the outcomes of patients, but in parallel has changed the frequency and epidemiology of infections. Hence, the great strides in the indications and use of new active treatments for MM need parallel progresses on the best approach to prophylaxis and supportive therapy for infections. Moving from the recognition that the above issue represents an unmet clinical need in MM, an expert panel assessed the scientific literature and composed a framework of recommendations for optimal infection control in patients candidate to active treatment for MM. The present publication represents a consensus document from questionnaires and consensus meetings held during 2017. The issues tackled in the project dealt with: infectious risk assessment, risk management and prophylaxis, intravenous immunoglobulin replacement therapy, antiviral and antibacterial vaccination. Considering the lack of conclusive and/or enough large studies for certain topics several recommendations derived from the personal experience of the experts.

AB - The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors, immunoregulatory drugs and monoclonal antibodies, has improved the outcomes of patients, but in parallel has changed the frequency and epidemiology of infections. Hence, the great strides in the indications and use of new active treatments for MM need parallel progresses on the best approach to prophylaxis and supportive therapy for infections. Moving from the recognition that the above issue represents an unmet clinical need in MM, an expert panel assessed the scientific literature and composed a framework of recommendations for optimal infection control in patients candidate to active treatment for MM. The present publication represents a consensus document from questionnaires and consensus meetings held during 2017. The issues tackled in the project dealt with: infectious risk assessment, risk management and prophylaxis, intravenous immunoglobulin replacement therapy, antiviral and antibacterial vaccination. Considering the lack of conclusive and/or enough large studies for certain topics several recommendations derived from the personal experience of the experts.

KW - Infections

KW - Multiple myeloma

KW - Prophylaxis

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85060186963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060186963&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2019.01.001

DO - 10.1016/j.blre.2019.01.001

M3 - Article

AN - SCOPUS:85060186963

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

ER -